NCT05096728View on ClinicalTrials.gov

Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)

CompletedOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 6, 2023

Study Completion Date

December 15, 2023

Conditions
Preeclampsia With Severe Features
Interventions
DRUG

Nifedipine XL

"Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg"

Trial Locations (1)

43210

The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus

All Listed Sponsors
lead

Ohio State University

OTHER

NCT05096728 - Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI) | Biotech Hunter | Biotech Hunter